148 related articles for article (PubMed ID: 17656591)
21. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
22. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
[TBL] [Abstract][Full Text] [Related]
23. Gender-related differences in non-functioning pituitary adenomas.
Schaller B
Neuro Endocrinol Lett; 2003 Dec; 24(6):425-30. PubMed ID: 15073569
[TBL] [Abstract][Full Text] [Related]
24. Predicting recurrence of nonfunctioning pituitary adenomas.
Noh TW; Jeong HJ; Lee MK; Kim TS; Kim SH; Lee EJ
J Clin Endocrinol Metab; 2009 Nov; 94(11):4406-13. PubMed ID: 19820025
[TBL] [Abstract][Full Text] [Related]
25. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
27. Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.
Pappy AL; Savinkina A; Bicknese C; Neill S; Oyesiku NM; Ioachimescu AG
Pituitary; 2019 Oct; 22(5):520-531. PubMed ID: 31432313
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A; Zatelli MC; Bianchi A; Cimino V; Tilaro L; Veltri F; Angelini F; Lauriola L; Vellone V; Doglietto F; Ambrosio MR; Maira G; Giustina A; degli Uberti EC; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2008 Jul; 93(7):2746-50. PubMed ID: 18460561
[TBL] [Abstract][Full Text] [Related]
29. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
30. A classification tree approach for pituitary adenomas.
Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
[TBL] [Abstract][Full Text] [Related]
31. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma.
Sanno N; Teramoto A; Osamura RY
J Neurosurg; 2000 Aug; 93(2):194-200. PubMed ID: 10930003
[TBL] [Abstract][Full Text] [Related]
32. Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients' characteristics.
Losa M; Donofrio CA; Barzaghi R; Mortini P
Eur J Endocrinol; 2013 Dec; 169(6):735-42. PubMed ID: 23999643
[TBL] [Abstract][Full Text] [Related]
33. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results.
Santoro A; Minniti G; Ruggeri A; Esposito V; Jaffrain-Rea ML; Delfini R
Surg Neurol; 2007 Nov; 68(5):513-8; discussion 518. PubMed ID: 17961741
[TBL] [Abstract][Full Text] [Related]
34. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
35. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker.
Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D
Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532
[TBL] [Abstract][Full Text] [Related]
36. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas.
Lv L; Hu Y; Yin S; Wang M; Zhou P; Zhang N; Ma W; Zhang S; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():93-98. PubMed ID: 29471288
[TBL] [Abstract][Full Text] [Related]
37. Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence.
Kirkman MA; Jaunmuktane Z; Brandner S; Khan AA; Powell M; Baldeweg SE
World Neurosurg; 2014 Dec; 82(6):1224-31. PubMed ID: 24657816
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase IIα as a prognostic factor in pituitary tumors.
Trofimiuk-Müldner M; Bałdys-Waligórska A; Sokołowski G; Adamek D; Hubalewska-Dydejczyk A; Gołkowski F
Pol Arch Med Wewn; 2014; 124(10):500-8. PubMed ID: 25692206
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of Ki-67 labeling index in pituitary macroadenoma.
Paek KI; Kim SH; Song SH; Choi SW; Koh HS; Youm JY; Kim Y
J Korean Med Sci; 2005 Jun; 20(3):489-94. PubMed ID: 15953875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
